The kynurenine pathway: A missing piece in the puzzle of valproate action?

Neuroscience

Volumn 234, Issue , 2013, Pages 135-145

  Maciejak, P ^a,b   Szyndler, J ^b   Turzynska D ^a   Sobolewska, A ^a   Kolosowska K ^b   Lehner, M ^a   Plaznik A ^a,b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Ibuprofen; Kynurenic acid; Kynurenine; Tryptophan; Valproate

Indexed keywords

IBUPROFEN; KYNURENIC ACID; KYNURENINE; SERUM ALBUMIN; SHORT CHAIN FATTY ACID; TRYPTOPHAN; VALPROIC ACID;

AMINO ACID BLOOD LEVEL; AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRYPTOPHAN BRAIN LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; IBUPROFEN; KYNURENIC ACID; KYNURENINE; MALE; RATS; SIGNAL TRANSDUCTION; TRYPTOPHAN; VALPROIC ACID;

EID: 84873494073     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.12.052     Document Type: Article

References (55)

1. Biggs C.S., Pearce B.R., Fowler L.J., Whitton P.S. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 1992, 59(5):1702-1708.
2. Chateauvieux S., Morceau F., Dicato M., Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010, 2010:479364.
3. Cheng L., Lumb M., Polgar L., Mudge A.W. How can the mood stabilizer VPA limit both mania and depression?. Mol Cell Neurosci 2005, 29:155-161.
4. Chronicle E, Mulleners W (2004) Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev CD003226.
5. Costa C., Martella G., Picconi B., Prosperetti C., Pisani A., Di Filippo M., Pisani F., Bernardi G., Calabresi P. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 2006, 37:1319-1326.
6. Curzon G., Friedel J., Knott P.J. The effect of fatty acids on the binding of tryptophan to plasma protein. Nature 1973, 242:198-200.
7. Dejong C.H., van de Poll M.C., Soeters P.B., Jalan R., Olde Damink S.W. Aromatic amino acid metabolism during liver failure. J Nutr 2007, 137:1579S-1585S.
8. Fehske K.J., Schläfer U., Wollert U., Müller W.E. Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone. Mol Pharmacol 1981, 21:387-393.
9. Fernstrom J.D. Branched-chain amino acids and brain function. J Nutr 2005, 135. 1539S-46S.
10. Fleitman J.S., Bruni J., Perrin J.H., Wilder B.J. Albumin-binding interactions of sodium valproate. J Clin Pharmacol 1980, 20:514-517.
11. Foster A.C., Vezzani A., French E.D., Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 1984, 48:273-278.
12. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., Smith Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991, 56:2007-2017.
13. Herve C., Beyne P., Jamault H., Delacoux E. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J Chromatogr B Biomed Appl 1996, 675:157-161.
14. Hicks R.R., Smith D.H., Gennarelli T.A., McIntosh T. Kynurenate is neuroprotective following experimental brain injury in the rat. Brain Res 1994, 655:91-96.
15. Hwang E.C., Van Woert M.H. Effect of valproic and acid on serotonin metabolism. Neuropharmacology 1979, 18:391-397.
16. James J.H., Ziparo Y., Jeppson B., Fischer J.E. Hyperammonaemia plasma amino acid imbalance, and blood-brain amino acid transport: a unified theory of portasystemic encephalopathy. Lancet 1979, 13(8146):772-775.
17. Kabakus N., Ay I., Aysun S., Söylemezoglu F., Ozcan A., Celasun B. Protective effects of valproic acid against hypoxic-ischemic brain injury in neonatal rats. J Child Neurol 2005, 20:582-587.
18. Kamiński R.M., Zielińska E., Dekundy A., van Luijtelaar G., Turski W. Deficit of endogenous kynurenic acid in the frontal cortex of rats with a genetic form of absence epilepsy. Pol J Pharmacol 2003, 55:741-746.
19. Kelly K.M., Gross R.A., Macdonald R.L. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci Lett 1990, 116:233-238.
20. Klivenyi P., Toldi J., Vecsei L. Kynurenines in neurodegenerative disorders: therapeutic consideration. Adv Exp Med Biol 2004, 541:169-183.
21. Kragh-Hansen U., Chuang V.T., Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002, 25:695-704.
22. Kratochwil N.A., Huber W., Müller F., Kansy M., Gerber P.R. Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 2002, 1:1355-1374.
23. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice: focus on individual differences. Pharmacol Biochem Behav 2010, 98(1):161-168.
24. Leng Y., Chuang D.M. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006, 26:7502-7512.
25. Löscher W. Basic pharmacology of valproate: a review after 35 year of clinical use for the treatment of epilepsy. CNS Drugs 2002, 16:669-694.
26. Löscher W., Siemes H. Valproic acid increases gamma-aminobutyric acid in CSF of epileptic children. Lancet 1984, 2:225.
27. Maciejak P., Lehner M., Turzyńska D., Szyndler J., Bidziński A., Taracha E., Sobolewska A., Walkowiak J., Skórzewska A., Wisłowska A., Hamed A., Płaźnik A. The opposite role of hippocampal mGluR1 in fear conditioning in kindled and non-kindled rats. Brain Res 2008, 1187:184-193.
28. Maciejak P., Szyndler J., Turzyńska D., Sobolewska A., Płaźnik A. Kynurenic acid: a new effector of valproate action?. Pharmacol Rep 2011, 63:1569-1573.
29. Maes M., Calabrese J., Jayathilake K., Meltzer H.Y. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res 1997, 71(2):67-76.
30. Maes M., Galecki P., Verkerk R., Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett 2011, 32(3):264-273.
31. Mandula H., Parepally J.M., Feng R., Smith Q.R. Role of site-specific binding to plasma albumin in drug availability to brain. J Pharmacol Exp Ther 2006, 317:667-675.
32. Mcmenamy R.H., Lund C.C., Neville G.J., Wallach D.F. Studies of unbound amino acid distributions in plasma, erythrocytes, leukocytes and urine of normal human subjects. J Clin Invest 1960, 39:1675-1687.
33. Meunier H., Carraz G., Meunier Y., Eymard P., Aimard M. Propriétés pharmacodynamiques de l'acide n-dipropylacétique. Thérapie 1963, 18:435-438.
34. Monti B., Polazzi E., Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2009, 2:95-109.
35. Myint A.M., Kim Y.K., Verkerk R., Scharpé S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007, 98:143-151.
36. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego, CA.
37. Perucca E. Pharmacological and therapeutic properties of Valproate: a summary after 35 years of clinical experience. CNS Drugs 2002, 16:695-714.
38. Rozsa E., Robotka H., Nagy D., Farkas T., Sas K., Vecsei L., Toldi J. The pentylenetetrazole-induced activity in the hippocampus can be inhibited by the conversion of L-kynurenine to kynurenic acid: an in vitro study. Brain Res Bull 2008, 76:474-479.
39. Scharfman H.E., Ofer A. Pretreatment with L-kynurenine, the precursor to the excitatory amino acid antagonist kynurenic acid, suppresses epileptiform activity in combined entorhinal/hippocampal slices. Neurosci Lett 1997, 224:115-118.
40. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002, 303:1-10.
41. Sinn D.I., Kim S.J., Chu K., Jung K.H., Lee S.T., Song E.C., Kim J.M., Park D.K., Kun Lee S., Kim M., Roh J.K. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis 2007, 26:464-472.
42. Sjoholm I., Ekman B., Kober A., Ljungstedt-Pahlman I., Seiving B., Sjodin T. Binding of drugs to human serum albumin: I. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Pharmacol 1979, 16:767-777.
43. Stone T.W. Comparison of kynurenic acid and 2-APV suppression of epileptiform activity in rat hippocampal slices. Neurosci Lett 1988, 84:234-238.
44. Stone T.W., Forrest C.M., Darlington L.G. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J 2012, 279:1386-1397.
45. Sudlow G., Birkett D.J., Wade D.N. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975, 11:824-832.
46. Sullivan P.A., Murnaghan D., Callaghan N., Kantamaneni B.D., Curzon G. Effect of dialysis on plasma and CSF tryptophan and CSF 5-hydroxyindoleacetic acid in advanced renal disease. J Neurol Neurosurg Psychiatry 1980, 43:739-743.
47. Szyndler J., Maciejak P., Turzyńska D., Sobolewska A., Walkowiak J., Płaźnik A. The effects of electrical hippocampal kindling of seizures on amino acids and kynurenic acid concentrations in brain structures. J Neural Transm 2012, 119:141-149.
48. Turski W.A., Gramsbergen J.B., Traitler H., Schwarcz R. Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. J Neurochem 1989, 52(5):1629-1636.
49. Vamos E., Pardutz A., Klivenyi P., Toldi J., Vecsei L. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci 2009, 283:21-27.
50. VanDongen A.M., VanErp M.G., Voskuyl R.A. Valproate reduces excitability by blockage of sodium and potassium conductance. Epilepsia 1986, 27:177-182.
51. Vecsei L., Miller J., MacGarvey U., Beal M.F. Kynurenine and probenecid inhibit pentylenetetrazol- and NMDA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res Bull 1992, 28:233-238.
52. Whitton P.S., Fowler L.J. The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur J Pharmacol 1991, 200:167-169.
53. Wu H.Q., Baran H., Ungerstedt U., Schwarcz R. Kynurenic acid in the quinolinate-lesioned rat hippocampus: studies in vitro and in vivo. Eur J Neurosci 1992, 4:1264-1270.
54. Zadori D., Klivenyi P., Vamos E., Fulop F., Toldi J., Vecsei L. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm 2009, 116:1403-1409.
55. Zeise M.L., Kasparow S., Zieglgänsberger W. Valproate suppresses N-methyl-d-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 1991, 544:345-348.